Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01873170 · ClinicalTrials.gov registry record
Quantification of Immune Cells in Women Using Contraception (CHIC II)
A clinical trial of HIV and Contraception, sponsored by University of Pittsburgh.
- Completed
- Registry status
- 326
- Enrollment target
- 1
- Study location
NCT01873170: Completed study of HIV and Contraception, sponsored by University of Pittsburgh.
NCT01873170 is a study of HIV and Contraception that has completed, run by University of Pittsburgh. The registered enrollment target is 326 participants, below the 439-participant average among 303 other HIV trials with a reported enrollment target (26% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01873170, a study of HIV and Contraception, has completed, sponsored by University of Pittsburgh.
- COMPLETED
- Registry status
- 326 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is being done to understand if using birth control causes changes in the immune cells within the reproductive tract (including the cervix and the lining of the uterus) of healthy women. Immune cells are important because they help prevent infections from starting and help fight infections that have started. Immune cells are also the type of cells that HIV (human immunodeficiency virus) infects so understanding more about them will help to better understand how to prevent the spread of HIV. Immune cells will be studied from the reproductive tract of women who want to start using one of the following contraceptives: an oral contraceptive pill (COC), Depo-Provera (DMPA), the levonorgestrel IUD (Mirena®), the copper IUD (ParaGard®), or the etonogestrel subdermal implant (Nexplanon®).Immune cells will also be studied from the reproductive tract of women who are not using birth control and who are not at risk of pregnancy for comparison.
Primary Outcome
To quantify and characterize immune cell populations and HIV-tropic receptor expression in the upper and lower genital tract and blood at baseline and after 3 and 6 months of typical contraceptive use
Conditions Studied
Interventions
- DRUG levonorgestrel exposure
- DRUG DMPA exposure
- DRUG etonogestrel exposure
- DEVICE IUD insertion
- DEVICE subdermal contraceptive implant insertion
Study Locations (1)
Pennsylvania
- Center for Family Planning Research - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 326 participants |
| Start Date | 2013-08 |
| Est. Completion | 2020-10 |
What the finished NCT01873170 record still lists
NCT01873170 is an observational study that tracks outcomes without assigning an intervention. The registered 326 participants enrollment target is mid-sized for trials with a published cap, below the 439-participant average among 303 other HIV trials with a reported enrollment target (26% lower).
The record links to 3 conditions, with HIV appearing as the primary indexed condition, and to 5 interventions - of which levonorgestrel exposure is the first listed.
NCT01873170 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT01873170 about?
NCT01873170 is a clinical study titled "Quantification of Immune Cells in Women Using Contraception (CHIC II)". This study is being done to understand if using birth control causes changes in the immune cells within the reproductive tract (including the cervix and the lining of the uterus) of healthy women. Immune cells are important because they help prevent infections from starting and help fight infections...
What is the current status of trial NCT01873170?
This trial is currently completed. The enrollment target is 326 participants. The study started on 2013-08. Estimated completion is 2020-10.
What conditions does trial NCT01873170 study?
This clinical trial studies the following conditions: HIV, Contraception, Immune Cells (Mucosal and Systemic).
What interventions are being tested in trial NCT01873170?
The interventions under investigation include: levonorgestrel exposure (DRUG), DMPA exposure (DRUG), etonogestrel exposure (DRUG), IUD insertion (DEVICE), subdermal contraceptive implant insertion (DEVICE).
Who is sponsoring clinical trial NCT01873170?
This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01873170 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01873170's enrollment target sits among peer trials
326 64th of 303 higher than 239 of 303 other HIV trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other HIV trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Transitional Housing and HIV Health
RECRUITING
-
Clinical Trial to Evaluate the Safety and Immunogenicity of a Priming Regimen of 426c.Mod.Core-C4b Followed by HxB2.WT.Core-C4b Boosts, Both Adjuvanted With 3M-052 AF + Alum, in Adult Participants Without HIV and in Overall Good Health
RECRUITING · Phase 1
-
Leukapheresis Procedures to Obtain Plasma and Lymphocytes for Research Studies on Antiretroviral Naive HIV-1 Research Participants
RECRUITING
-
Evaluating Gardasil HPV Vaccine Humoral and Cellular Immune Responses in People With and Without HIV
RECRUITING · Phase 2
-
Text Education About Cardiovascular Health and HIV (TEACH-HIV)
RECRUITING · NA
-
1MoreStep: An Intervention to Increase HIV Care Engagement and Reduce Intimate Partner Violence Among Black Women Living With HIV
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06410144 · 326 participants · NA
Chronic Kidney Disease-Education (CKD-EDU)
- NCT07040566 · 326 participants · Phase 2
A Trial of Varenicline for E-cigarette Cessation
- NCT07165860 · 326 participants · NA
Clinical Trial to Reduce Perinatal Intimate Partner Violence
- NCT04486378 · 327 participants · Phase 2
A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia